Vivek Ramaswamy Popular Books

Vivek Ramaswamy Biography & Facts

Vivek Ganapathy Ramaswamy (; vih-VAYK rah-mə-SWAH-mee; born August 9, 1985) is an American entrepreneur and politician. He founded Roivant Sciences, a pharmaceutical company, in 2014. In February 2023, Ramaswamy declared his candidacy for the Republican Party nomination in the 2024 United States presidential election. He suspended his campaign in January 2024, after finishing fourth in Iowa's caucuses.Ramaswamy was born in Cincinnati to Indian immigrant parents. He graduated from Harvard College with a bachelor's degree in biology and later earned a law degree from Yale Law School. Ramaswamy worked as an investment partner at a hedge fund before founding Roivant Sciences. He also co-founded an investment firm, Strive Asset Management. Ramaswamy claims the United States is in the middle of a national identity crisis precipitated by what he calls "new secular religions like COVID-ism, climate-ism, and gender ideology". He is also a critic of environmental, social, and corporate governance initiatives (ESG). In January 2024, Forbes estimated Ramaswamy's net worth at more than $960 million; his wealth comes from biotech and financial businesses. Early life and education Vivek Ganapathy Ramaswamy was born on August 9, 1985, in Cincinnati, Ohio, to Indian Hindu immigrant parents. His parents are Tamil-speaking Brahmins from Kerala. His father, V. Ganapathy Ramaswamy, a graduate of the National Institute of Technology Calicut, worked as an engineer and patent attorney for General Electric, while his mother, Geetha Ramaswamy, a graduate of the Mysore Medical College & Research Institute, worked as a geriatric psychiatrist. His parents immigrated from Palakkad district in Kerala, where the family had an ancestral home in a traditional agraharam in the town of Vadakkencherry.Ramaswamy was raised in Ohio. Growing up, Ramaswamy often attended the local Hindu temple in Dayton with his family. His conservative Christian piano teacher, who gave him private lessons from elementary through high school, also influenced his social views. He spent many summer vacations traveling to India with his parents. In high school, Ramaswamy was a nationally ranked tennis player. Education Ramaswamy attended public schools through eighth grade. He then attended Cincinnati's St. Xavier High School, a Catholic school affiliated with the Jesuit order, graduating as valedictorian in 2003.In 2007, Ramaswamy graduated from Harvard University with a Bachelor of Arts, summa cum laude, in biology, and was a member of Phi Beta Kappa. At Harvard, he gained a reputation as a brash and confident libertarian. He was a member of the Harvard Political Union, becoming its president. He told The Harvard Crimson that he considered himself a contrarian who loved to debate. While in college, he performed Eminem covers and libertarian-themed rap music under the stage name and alter ego "Da Vek", and was an intern for the hedge fund Amaranth Advisors and the investment bank Goldman Sachs. He wrote his senior thesis on the ethical questions raised by creating human-animal chimeras and earned a Bowdoin Prize.In 2011, Ramaswamy was awarded a post-graduate fellowship by the Paul & Daisy Soros Fellowships for New Americans, which he used to attend Yale Law School. Later, Ramaswamy said that by the time he attended Yale, he was already wealthy from his activities in the finance, pharmaceutical, and biotech industries; he said in 2023 that he had a net worth of around $15 million before graduating from law school. At Yale he befriended fellow Ohio native and future U.S. Senator J. D. Vance. He earned a Juris Doctor in 2013. In a 2023 interview, Ramaswamy said that he was a member of the campus Jewish intellectual discussion society Shabtai while a law student. Career Early career In 2007, Ramaswamy and Travis May co-founded Campus Venture Network, which published a private social networking website for university students who aspired to launch a business. The company was sold to the nonprofit Ewing Marion Kauffman Foundation in 2009.Ramaswamy worked at the hedge fund QVT Financial from 2007 to 2014. He was a partner and co-managed the firm's biotech portfolio. QVT's biotech investments under Ramaswamy included stakes in Palatin Technologies, Concert Pharmaceuticals, Pharmasset, and Martin Shkreli's Retrophin. In a 2023 speech and in his book Woke Inc., Ramaswamy called Shkreli, whose company had greatly increased the cost of a life-saving drug, both "brilliant" and a pathological liar. He criticized the U.S. Department of Justice for prosecuting Shkreli, calling his fraud a victimless crime. Roivant Sciences and subsidiaries In 2014, Ramaswamy founded the biotechnology firm Roivant Sciences; the "Roi" in the company's name refers to return on investment. The company was incorporated in Bermuda, a tax haven, and received almost $100 million in start-up capital from QVT and other investors, including RA Capital Management, Visium Asset Management, and the hedge fund managers D. E. Shaw & Co. and Falcon Edge Capital. Roivant's strategy was to purchase patents from larger pharmaceutical companies for drugs that had not yet been successfully developed, and then bring them to the market. The company created numerous subsidiaries, including Dermavant (focused on dermatology), Urovant (focused on urological disease), and China-based Sinovant and Cytovant, focused on the Asian market.In 2015, Ramaswamy raised $360 million for the Roivant subsidiary Axovant Sciences in an attempt to market intepirdine as a drug for Alzheimer's disease. In December 2014, Axovant purchased the patent for intepirdine from GlaxoSmithKline (where the drug had failed four previous clinical trials) for $5 million, a small sum in the industry. Ramaswamy appeared on the cover of Forbes in 2015, and said his company would "be the highest return on investment endeavor ever taken up in the pharmaceutical industry." Before new clinical trials began, he engineered an initial public offering (IPO) in Axovant. Axovant became a "Wall Street darling" and raised $315 million in its IPO. The company's market value initially soared to almost $3 billion, although at the time it only had eight employees, including Ramaswamy's brother and mother. Ramaswamy took a massive payout after selling a portion of his shares in Roivant to Viking Global Investors. He claimed more than $37 million in capital gains in 2015. Ramaswamy said his company would be the "Berkshire Hathaway of drug development" and touted the drug as a "tremendous" opportunity that "could help millions" of patients, prompting some criticism that he was overpromising.In September 2017, the company announced that intepirdine had failed in its large clinical trial. The company's value plunged; it lost 75% in one day and continued to decline afterward. Shareholders who lost money included various institutional investors, such as the California State Teachers' Retirement System pension fund. Ramaswamy .... Discover the Vivek Ramaswamy popular books. Find the top 100 most popular Vivek Ramaswamy books.